Health Innovation
From Invention to Startup: 5 Health Founders Bringing Their Technology to Market
DealBio tracks early-stage health startups across Europe and North America. These 5 are built around technologies their founders helped create through years of academic, clinical or technical research, then carried directly into a startup.
- Academic Founders
- Patented Technology
- Medtech
- Biotech
- Diagnostics
That continuity gives each startup a valuable starting advantage: the founders understand the mechanism, experimental limits and patent history behind the core technology, and can use that knowledge to shape product design, validation and IP strategy from the outset.
Across compact MRI, antivirals, antibody engineering, microneedle delivery and Parkinson’s diagnostics, the founder is not simply commercializing someone else’s invention. The scientific work and the venture remain closely connected as the technology moves toward real-world use.
At a Glance
- AdialanteUnited States2023Compact MRI
- Astremiha TherapeuticsFrance2024Host-directed antiviral platform
- Aventera AntibodiesSweden2025Engineered antibacterial antibody
- Maman BiomedicalCanada2024Microneedle fertility-drug delivery
- NeuroTidal DiagnosticsNetherlands2026Protein-aggregate diagnostics
Making compact mobile MRI screening accessible outside traditional imaging centers.
- Country
United States- Founded
- 2023
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why Adialante stands out
Adialante is built around MRI methods co-invented by CEO Efraín Torres. Torres and University of Minnesota MRI physicist Michael Garwood are named on two issued US patents covering radiofrequency spatial encoding, an MRI approach designed to reduce dependence on conventional gradient hardware.
The startup has moved the invention toward a commercial screening model, reporting $19.75 million in signed letters of intent across 11 clinics and more than $3 million in non-dilutive funding.
What Adialante is building
Adialante is developing a compact mobile MRI system intended for screening outside conventional imaging centers. Its radiofrequency encoding approach is designed to reduce dependence on the large gradient hardware used in traditional MRI.
The startup is initially targeting urology clinics, where a smaller system could bring imaging closer to patients and reduce the infrastructure required for screening.
Advancing broad-spectrum antivirals for HIV, Long COVID, and viral infections.
- Country
France- Founded
- 2024
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Astremiha Therapeutics stands out
Astremiha Therapeutics commercializes antiviral compounds developed through around 15 years of academic research. Co-founder Mireille Laforge is a named inventor on the therapeutic intellectual property originating from French public research institutions.
The startup has filed three patents around next-generation antiviral compounds and received €500,000 in early financing from investors and Bpifrance, France’s public investment bank.
What Astremiha Therapeutics is building
Astremiha Therapeutics is developing host-directed antivirals, medicines designed to act on human-cell pathways that viruses depend on rather than only targeting a viral protein. Its first programs focus on HIV and Long COVID.
By targeting host biology, the platform is intended to address persistent infection and viral reservoirs, cells or tissues where a virus can remain difficult to eliminate, while retaining a route to broader antiviral applications.
Developing an engineered antibody for severe invasive Group A strep infections.
- Country
Sweden- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Aventera Antibodies stands out
Aventera Antibodies is commercializing antibody science developed by its founders at Lund University. Pontus Nordenfelt is named on the M-protein antibody patent family, while both Nordenfelt and Arman Izadi are inventors on a second family covering antibody hinge engineering, modifying the flexible joint between an antibody’s arms and tail to change immune-cell engagement.
The startup raised SEK 14.5 million in a round led by LU Ventures and has reported animal proof of concept with a lead active across multiple bacterial strains.
What Aventera Antibodies is building
Aventera Antibodies is developing AV01, a monoclonal antibody, a laboratory-made antibody produced in identical copies to bind one target, for severe invasive Group A streptococcal infections, in which the bacterium reaches blood, muscle or other normally sterile tissue.
The antibody targets M protein, a major surface protein that helps Group A strep avoid immune clearance, while leaving its immune-active tail exposed so immune cells can recognize and clear the bacterium alongside antibiotic treatment.
Developing needle-free microneedle devices for fertility hormone delivery.
- Country
Canada- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Maman Biomedical stands out
Maman Biomedical is led by inventor-founder Latchmi Raghunanan, who has a materials-science background and is named on granted patents from earlier research. The startup now owns three patent families and has filed five US and Canadian applications covering its hollow and dissolving microneedle formats.
The team has also completed an FDA Pre-Submission meeting, a formal process for obtaining FDA feedback before a device submission, which clarified the Maman Port 510(k) pathway. A 510(k) is the US clearance route used when a device can show substantial equivalence to a legally marketed device. The startup has also secured more than $500,000 in non-dilutive funding.
What Maman Biomedical is building
Maman Biomedical is developing microneedle devices, arrays of tiny needles that enter the outer layers of skin, to deliver prescribed fertility hormones without a conventional hypodermic needle. Maman Port is designed to work with existing injectable medicines while changing the delivery device.
The platform also includes a dissolving microneedle patch for sustained delivery and an earlier-stage wearable concept, giving the startup multiple product routes from the same delivery expertise.
Developing a blood test to detect Parkinson's disease and measure its stage.
- Country
Netherlands- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why NeuroTidal Diagnostics stands out
NeuroTidal Diagnostics is commercializing protein-measurement technology developed at Utrecht University. Françoise Dekker and Stefan Rüdiger are named inventors on the university patent application covering the FibrilPaint detection molecules.
The underlying method was published in PNAS using patient-derived brain tissue, while the startup has received €200,000 through Biotech Booster, a Dutch national program supporting commercialization of biotechnology research.
What NeuroTidal Diagnostics is building
NeuroTidal Diagnostics is developing FibrilRuler, a test that uses fluorescent FibrilPaint molecules to bind misfolded protein aggregates, clumps of incorrectly folded proteins associated with Parkinson’s disease.
The startup aims to detect and size those aggregates in blood or cerebrospinal fluid, the clear fluid surrounding the brain and spinal cord, creating an objective measurement that could support diagnosis, staging and disease monitoring.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Inventor-founders carry technical depth into commercialization
The strongest common signal across the five is continuity between inventor and venture. The founders remain close to the technical decisions because they helped create the underlying methods, molecules or devices, giving the startups direct access to years of accumulated knowledge that is difficult to transfer through patents alone.
That background can strengthen product development in practical ways: identifying which parts of the technology are genuinely differentiated, protecting the right IP, designing validation around the mechanism and making trade-offs without losing the original scientific logic. These startups therefore begin commercialization with both a technical asset and founders who already understand it at a deep level.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on ventures where a founder is a named inventor, patent contributor or documented originator of the core technology being commercialized. The selection spans medtech, biotech and diagnostics to show different routes from invention to market.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.